v3.26.1
Identifiable Intangible Assets, Net and Goodwill (Tables)
 6 Months Ended
Jun. 28, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Intangible Asset, Finite-Lived
The following summarizes the components of Identifiable intangible assets:
June 28, 2026December 31, 2025
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$100,799 $(72,512)$28,287 $100,630 $(70,172)$30,458 
Brands1,035 (1,035)— 1,035 (1,035)— 
Licensing agreements and other2,364 (1,378)986 2,341 (1,289)1,052 
104,198 (74,925)29,273 104,006 (72,496)31,510 
Indefinite-lived intangible assets
IPR&D(a)
17,320 17,320 21,760 21,760 
Licensing agreements and other
460 460 460 460 
17,780 17,780 22,221 22,221 
Identifiable intangible assets
$121,978 $(74,925)$47,053 $126,227 $(72,496)$53,731 
(a)The gross carrying amounts as of June 28, 2026 reflect impairments of $3.8 billion in IPR&D assets and $525 million in developed technology rights (see Note 4). The gross carrying amounts also reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).
Schedule of Indefinite Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
June 28, 2026December 31, 2025
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$100,799 $(72,512)$28,287 $100,630 $(70,172)$30,458 
Brands1,035 (1,035)— 1,035 (1,035)— 
Licensing agreements and other2,364 (1,378)986 2,341 (1,289)1,052 
104,198 (74,925)29,273 104,006 (72,496)31,510 
Indefinite-lived intangible assets
IPR&D(a)
17,320 17,320 21,760 21,760 
Licensing agreements and other
460 460 460 460 
17,780 17,780 22,221 22,221 
Identifiable intangible assets
$121,978 $(74,925)$47,053 $126,227 $(72,496)$53,731 
(a)The gross carrying amounts as of June 28, 2026 reflect impairments of $3.8 billion in IPR&D assets and $525 million in developed technology rights (see Note 4). The gross carrying amounts also reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).